Trastuzumab (Herceptin) is a recombinant humanized monoclonal antibody (mAb) directed against an extracellular region of the human epidermal growth-factor receptor type 2 (HER2) protein. We hypothesized that a single adeno-associated virus (AAV)mediated genetic delivery of an anti-HER2 antibody should be effective in mediating long-term production of anti-HER2 and in suppressing the growth of human tumors in a xenograft model in nude mice. The adeno-associated virus gene transfer vector AAVrh.10aHER2 was constructed based on a non-human primate AAV serotype rh.10 to express the complementary DNAs for the heavy and light chains of mAb 4D5, the murine precursor to trastuzumab. The data show that genetically transferred anti-HER2 selectively bound human HER2 protein and suppressed the proliferation of HER2 þ tumor cell lines. A single administration of AAVrh.10aHER2 provided long-term therapeutic levels of anti-HER2 antibody expression without inducing an anti-idiotype response, suppressed the growth of HER2 þ tumors and increased the survival of tumor bearing mice. In the context that trastuzumab therapy requires frequent and repeated administration, this strategy might be developed as an alternate platform for delivery of anti-HER2 therapy.
Introduction
Human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu or ErbB-2) is a 185 kDa tyrosine kinase cell surface receptor. 1 HER2 was originally identified as a proto-oncogene and is known to be overexpressed and/or amplified in many types of human malignancies, such as breast, ovarian, stomach, salivary gland and kidney tumor. 2 Overexpression of HER2, with subsequent constitutive kinase activation, is observed in approximately 20-30% of human breast cancers and is associated with reduced disease-free and overall survival. 3, 4 A variety of anti-HER2 therapies effectively suppress the growth of HER2-dependent tumors in experimental models. [5] [6] [7] Trastuzumab (Herceptin), a recombinant humanized monoclonal antibody (mAb) directed against an extracellular region of the HER2 protein, was the first HER2-targeted therapy approved by the United States Food and Drug Administration for the treatment of HER2-overexpressing metastatic breast cancer. 8 Clinical trials have established that addition of trastuzumab to adjuvant chemotherapy (either in sequence or in combi-nation) resulted in significant improvements in diseasefree and overall survival rates in patients with early-stage HER2-overexpressing breast cancer. 8 Trastuzumab is administered either once a week or once every 3 weeks intravenously for 30-90 min to achieve a minimum trough serum level of 410 mg ml À1 . 9 As follow-up treatment is indefinite, this places a substantial burden on patients and the health-care system in terms of time and cost.
With the aim of developing an alternative platform for delivering trastuzumab, we hypothesized that genetic delivery of an anti-HER2 antibody with the trastuzumab antigen-binding site should be effective in suppressing the growth of human tumors. An adeno-associated virus (AAV) gene transfer vector (AAVrh.10aHER2) was constructed based on the non-human primate AAV serotype rh.10 expressing complementary DNA for the heavy and light chains of mAb 4D5, the murine precursor to trastuzumab. The data show that following a single administration to mice, the AAVrh.10aHER2 vector expressed persistent levels of an antibody that selectively bound human HER2 protein and suppressed the proliferation of the HER2 þ tumor cell line and the tumor in vivo, and increased the survival of HER2 þ human tumor-bearing nude mice.
Materials and Methods
Anti-HER2 expression cassette Molecular clones of HER2 antibody heavy and light chains were amplified from mouse anti-human HER2 hybridoma 4D5 (American Type Culture Collection, Manassas, VA). The antigen-binding regions of 4D5 correspond to those in trastuzumab. 10 pAAVaHER2 and pAAVaHER2-myc are plasmids used to express fulllength HER2 antibody in a single open-reading frame in an AAV vector. The anti-HER2 expression cassettes contain (5 0 -3 0 ) the cytomegalovirus immediate early promoter/enhancer followed by complementary DNA encoding anti-HER2 heavy chain, a 13 amino-acid myc tag (only for aHER2-myc), a 4-amino-acid furin cleavage site, a 24-amino-acid self-cleaving 2A peptide from footand-mouth disease virus, the anti-HER2 light chain and the bovine growth hormone polyadenylation signal. 11, 12 The AAVaHER2 and AAVaHER2-myc expression cassettes are both flanked by the inverted terminal repeats of AAV2.
Adeno-associated virus vectors
AAVrh.10aHER2 and AAVrh.10aHER2-myc are AAV gene transfer vectors expressing full-length anti-HER2 antibody. 11 AAVrh.10aPA-myc expresses an unrelated antibody against anthrax protective antigen and was used as a negative control vector. 13 AAVrh.10 vectors expressing green fluorescent protein (AAVrh.10GFP) and LacZ expression cassettes were used as further controls. 11, 13 All AAV vectors were based on rh.10, a non-human primatederived AAV that provides high efficiency of gene transfer. 11, 13 The vectors were produced using three plasmids: (1) an expression plasmid described above containing (5 0 -3 0 ) the AAV2 inverted terminal repeats including the packaging signal, the expression cassette and the 3 0 AAV2 inverted terminal repeats; (2) pAAV44.2, a plasmid that provides rep proteins derived from AAV2 and cap proteins derived from AAVrh.10; 11, 13 and (3) pAdDeltaF6, an adenovirus helper plasmid that provides the adenovirus helper functions of E2, E4 and VA RNA. To create the vectors, the expression plasmid (600 mg), pAAV44.2 (800 mg) and pAdDeltaF6 (1200 mg) were co-transfected into human embryonic kidney 293 cells with Polyfect (Qiagen, Valencia, CA). At 72 h post-transfection, cells were harvested, a crude viral lysate was prepared by three freeze/thaw cycles and clarified by centrifugation. The AAV vectors were purified by iodixinol gradient and Q Sepharose HP anion exchange chromatography. The purified AAV vectors were concentrated using a BioMax 100 membrane concentrator (Millipore, Billerica, MA) and stored in phosphate-buffered saline (PBS), pH 7.4 at À80 1C. 11, 13 Vector genome titers were determined by TaqMan real-time polymerase chain reaction using a cytomegalovirus promoter-specific primer-probe set, designed using Primer Express software (Applied Biosystems, Foster City, CA). An AAVa1AT plasmid DNA standard of known copy number was used to generate a standard curve. 11 The control AAV6.2 vectors expressing lacZ transgene were generated using a similar method but with the pAAV6.2 AAV helper plasmid with the AAV6.2 capsid sequence instead of the p44.2 AAV helper plasmid. 14, 15 Cell lines BT474 breast cancer, SK-BR-3 breast cancer and Calu-3 lung cancer cell lines are HER2 þ human tumor cell lines. [16] [17] [18] A-673 rhabdomyosarcoma and HeLa cervical cancer are HER2 À human tumor cell lines and BEAS-2b is an immortalized bronchial epithelial HER2 À cell line. [19] [20] [21] All these cell lines were obtained from the American Type Culture Collection and maintained in a medium recommended by the American Type Culture Collection.
In vitro assessment of anti-HER2 expression
To assess the function of expressing cassettes, expression of the anti-HER2 antibody from pAAVaHER2 and pAA-VaHER2-myc was examined following transfection of cells in vitro using western blot analysis. 293 cells were transfected with pAAVaHER2 or pAAVaHER2-myc (8 mg plasmids per 10 cm plate) and the transfected cell medium was harvested at 72 h post-transfection. Media from mock and pGFP-transfected (a plasmid expressing green fluorescent protein) cells served as negative controls. Media from pAAVaPA-myc-transfected cells and purified mouse IgG1 served as additional controls. All media were evaluated for the expression of anti-HER2 antibody by western blot analysis under non-reducing and reducing conditions using a sheep anti-mouse IgG heavy chain and light chain secondary antibody (Sigma, Saint Louis, MO) and enhanced chemiluminescence reagent (Amersham, Piscataway, NJ). Peroxidase-conjugated mouse anti-myc antibody (GeneTex, San Antonio, TX) was used to detect the myc-tagged antibody heavy chain under non-reducing and reducing conditions. The specificity of the AAV plasmids expressing anti-HER2 antibodies for human HER2 was evaluated by immunohistochemistry. HER2 þ SK-BR-3 and HER2 À BEAS-2b cells were fixed by 4% paraformaldehyde and blocked with 5% goat serum. After washing, the cells were incubated with the medium from pAAVaHER2-, pAAVaHER2-myc-or pAAVaPA-myc-transfected 293 cells for 60 min. Cells were then washed and incubated with Alexa 488-labeled goat anti-mouse antibody (Jackson, West Grove, PA) at a dilution of 1:100 for 60 min. 4'-6-Diamidino-2-phenylindole (Invitrogen, Carlsbad, CA) was used to stain the nuclei. Labeled cells were assessed by fluorescent microscopy (Olympus IX 70, Olympus America, Center Valley, PA).
Cell proliferation
The anti-proliferation effect of the AAV plasmids expressing anti-HER2 antibody was assayed using the HER2 þ BT474 breast tumor cell line and the HER2 À HeLa cervical cancer cell line. Cells (10 4 per well) were plated in 96-well plates. Following cell adherence, the medium collected from 293 cells transfected with mock, pGFP, pAAVaPA-myc, pAAVaHER2 or pAAVaHER2myc was added (1:2 dilution, 8 wells per group). After incubation at 37 1C for 3 days, 20 ml per well of CellTiter 96 AQueous One Solution Reagent (Promega, Madison, WI) was added. After 1 h incubation, the absorbance at 490 nm was recorded using an ELISA plate reader.
The data were expressed as the ratio of A 490 for the experimental group relative to A 490 for the untransfected control group. For assessment of dose-dependent inhibition, the medium collected from 293 cells transfected with mock, pAAVaPA-myc, AAVaHER2 or pAAVaHER2myc was twofold serially diluted from 50 to 6.25% and then added to BT474 adhered cells. After 5 days, cell proliferation was assessed as described above.
Flow cytometry
Female C57Bl/6 mice, 6-8 weeks of age, were obtained from Taconic (Germantown, NY) and were housed under specific pathogen-free conditions. AAVrh.10aHER2-myc or, as controls, AAVrh.10LacZ or PBS (10 11 genome copies for the vectors) were administered by the intravenous route. To assess the expression of the anti-HER2 antibody in serum from AAVrh.10aHER2-myc-treated mice, HER2 þ BT474 and HER2 À A673 cell lines were chosen for binding-specificity determination. BT474 or A673 cells were trypsinized and resuspended in PBS containing 1% fetal bovine serum and then blocked with 5% goat serum in PBS for 20 min. After washing three times, BT474 or A673 cells were incubated with 1:40 diluted serum (collected at day 30 post-administration) from AAVrh.10aHER2-myc-treated mice for 60 min. Sera from PBS and AAVrh.a10aPA-myc treated mice served as negative controls. Cells were then washed and incubated with fluorescein isothiocyanate-labeled goat anti-mouse antibody (R&D Systems, Minneapolis, MN). After 30 min, cells were washed and assessed with a BD FACSCalibur cytometer (BD Biosciences, San Jose, CA) using CellQuest (BD Biosciences) and FlowJo (Tree Star, Ashland, OR) software.
Organ distribution of AAVrh.10 vector-mediated transgene expression following intravenous administration To evaluate organ distribution of the AAVrh.10 vector following intravenous administration, AAVrh.10-Luc (10 11 genome copies) in 100 ml PBS was administered intravenously into female C57BL/6 mice (n ¼ 6). As a control, the same volume of PBS was administered intravenously to three mice. At 3 weeks after administration, the animals were killed and tissues samples were collected from each animal, including the brain, heart, lung, diaphragm, liver, spleen, kidney, uterus and quadriceps muscle. The total weight of the organs was determined and then the organs were analyzed for luciferase transgene expression. The luciferase enzyme activity in homogenates of the individual organs was assessed, was represented as relative light units quantified in a luminometer (Promega) and was standardized by total protein concentration using a bicinchoninic acid assay (BioRad, Hercules, CA). The relative light units were also multiplied by the total organ weight. 11 Anti-HER2 antibody levels in mice following AAVrh.10aHER2-myc administration Anti-human HER2 antibody levels in the serum were assessed as a function of time in C57Bl/6 mice receiving AAVrh.10aHER2-myc (10 11 genome copies, intravenously) by western blot analysis and by a human HER2-specific ELISA. The western blot analysis was carried out under non-reducing conditions with an mycspecific antibody as described above. The HER2-specific ELISA was carried out using flat-bottomed 96-well enzyme immunoassay/radioimmunoassay plates (Corning, New York, NY) coated with a 0.3 mg extracellular domain of human HER2 per well in a total volume of 100 ml PBS overnight at 4 1C. The extracellular domain of HER2 was expressed as a His-tagged protein in 293 cells and was purified by nickel affinity chromatography (GE Healthcare, Piscataway, NJ). The coated ELISA plates were blocked with 5% dry milk, washed and 1:100 dilutions of mouse serum in PBS containing 1% dry milk were added to each well and incubated at 25 1C for 60 min. The plates were washed three times with PBS-Tween, and 100 ml per well of 1:10 000 diluted horseradish peroxidase-conjugated goat anti-mouse antibody (Santa Cruz Biotechnology, Santa Cruz, CA) in PBS containing 1% dry milk was added and incubated for 60 min. The plates were washed four times and peroxidase substrate (100 ml per well; Bio-Rad, Hercules, CA) was added; after 17 min, the reaction was stopped by addition of 2% oxalic acid (100 ml per well) and absorbance at 415 nm was measured. The standards were prepared by protein G column purification of anti-HER2 antibody from the supernatant of pAAVaHER2myc-transfected 293 cells. Antibody levels to human HER2 were estimated by calculating the antibody concentrations of a serially diluted standard of known concentration.
Anti-AAV and anti-idiotypic antibody responses
Anti-AAVrh.10 antibodies in the serum from AAVrh. 10aHER2-myc treated C57Bl/6 mice were assessed by ELISA. The sera from naive mice were used as controls. Flat-bottomed 96-well enzyme immunoassay/radioimmunoassay plates (Corning) were coated with 10 9 genome copies of AAVrh.10GFP per well or AAV6.2LacZ as control, in a total volume of 100 ml PBS overnight at 4 1C. Plates were then blocked with 5% dry milk and washed. Serum dilutions (1:100) in PBS containing 1% dry milk were added to each well and incubated for 60 min. Anti-AAVrh.10 antibodies were detected with horseradish peroxidase-conjugated goat anti-mouse antibody.
For analysis of a possible anti-idiotypic antibody response against the anti-HER2 antibody, the Fab fragment of anti-HER2-myc antibody was prepared from protein G column-purified full-length anti-HER2-myc protein using mouse IgG1 Fab and F(ab)2 Preparation Kit (Pierce, Rockford, IL). Flat-bottomed 96-well enzyme immunoassay/radioimmunoassay plates (Corning) were coated with 0.5 mg Fab fragment of anti-HER2-myc per well or with full-length anti-HER2-myc as control, in a total volume of 100 ml PBS overnight at 4 1C. The purity of the Fab fragment was assessed by ELISA using 1:8000 diluted horseradish peroxidase-conjugated sheep anti-mouse IgG heavy and light chain antibody, mouse anti-myc antibody (GeneTex) and goat anti-mouse Fc antibody (SIGMA). The specific binding to the HER2 protein by the Fab fragment was also assessed by HER2specific ELISA as described above. After purity determination, the Fab fragment of anti-HER2-myc was used to coat the plates and then blocked and washed as described above. The serum from AAVrh.10aHER2-myc-treated C57Bl/6 mice or naive mice was diluted 1:100 and then added to each well and incubated at 25 1C for 60 min. Anti-idiotypic antibodies were detected using horseradish peroxidase-conjugated goat anti-mouse Fc antibody.
Human tumor model
Female nude mice, 6-8 weeks of age, were obtained from Taconic and housed under specific pathogen-free conditions. On day 0, mice were treated by intravenous administration of 10 11 genome copies per mouse AAVrh. 10aHER2-myc or, as controls, AAVrh.10aPA-myc or PBS. Tumor cells (10 7 Calu-3) were injected subcutaneously in the right flank of the mice on day 21. The size of each tumor was measured using a calipers two times weekly and tumor volume was calculated as length Â width 2 Â 0.52. When the mice became morbid, the tumor ulcerated, tumor diameter reached 15 mm or tumor volume reached 1000 mm 3 , the mice were killed and this was recorded as the date of death.
Statistical analysis
All data are shown as mean ± s.e. Statistical comparison was made using the two-tailed Student's t-test and a value of Po0.05 indicating significance. Survival evaluation was carried out using Kaplan-Meier analysis.
Results

Characterization of the anti-HER2 antibody expression cassettes
To examine the expression of the anti-HER2 antibody by the expression cassettes, 293 cells were transfected with pAAVaHER2 and pAAVaHER2-myc or with pAA-VaPA-myc, pGFP and mock as controls. At 72 h, cell media were collected and antibody expression was examined by western blot analysis under non-reducing ( Figure 1a ) and reducing conditions ( Figure 1b ). Media collected from pAAVaHER2 and pAAVaHER2-myctransfected cells showed the presence of full-length antibody under non-reducing condition (lanes 10 and 11) and separated antibody heavy and light chains under reducing condition (lanes 22 and 23). The stoichiometry of the heavy and light chains was similar for the IgG control and the antibody expressed by the pAAVaHER2 vector (0.92 versus 1.02 by densitometry). The medium collected from pAAVaHER2-myc-transfected cells also showed the presence of myc tag-labeled heavy chain under reducing (lane 4) and non-reducing conditions (lane 16) . No antibody was detected in the medium from mocktransfected or pGFP-transfected cells.
The specificity of the anti-HER2 antibody expressed from the plasmids for human HER2 was first assessed by immunofluorescent staining. Media collected from pAAVaHER2-and pAAVaHER2-myc-transfected cells recognized HER2 þ SK-BR-3 cells (Figures 2a and b To assess whether the anti-HER2 antibody directed by the expression cassettes was functional, inhibition of cell growth was demonstrated in vitro with HER2 þ (BT474) and HER2 À (HeLa) cell lines. Cell growth was assessed after exposure to the medium from pAAVaHER2-, pAAVaHER2-myc-, pAAVaPA-myc-or pGFP-transfected 293 cells using the medium from mock-transfected cells as a control. When HeLa cells were used, there was no impact of any conditioned medium on the growth rate (P40.1 comparing all groups with the HeLa cells exposed to the conditioned medium of mock-transfected cells, Figure 3a ). After 3 days, treatment of BT474 cells with the medium from pAAVaPA or pGFP-transfected cells had no impact on growth rate compared with that of BT474 cells treated with mock-transfected cell media (P40.2). In contrast, BT474 cells treated with the medium from pAAVaHER2-or pAAVaHER2-myc-transfected cells showed suppression of growth relative to the controls (Po0.0001).
To determine the dose-dependent anti-tumor growth effect of anti-HER2 antibody, media from pAAVaHER2, pAAVaHER2-myc-and pAAVaPA-myc-transfected 293 cells were serially diluted from 1:2 to 1:16 and the impact on proliferation of BT474 HER2 þ cells was assessed (Figure 3b ). The anti-HER2 antibody showed a dosedependent anti-proliferation effect with more than 40% growth inhibition effect achieved when 1:2 dilutions of media containing anti-HER2 antibody were used (Po0.0001 compared with the growth rate of cells treated with the medium from pAAVaPA-transfected cells).
Distribution of transgene following intravenous administration of AAVrh.10 vectors
To determine the pattern of organ distribution of transgene expression directed by the AAVrh.10 serotype following intravenous administration, expression of luciferase following injection of AAVrh.10-Luc was assessed. Luciferase-specific activity was highest in the liver, with much smaller amounts of activity in the heart, diaphragm and quadriceps ( Figure 4a ) and negligible expression level in the spleen and thymus. When represented in terms of the total amount of luciferase expressed in each organ, the liver contributed to 88±4% of the total body luciferase activity (Figure 4b) , implying that the liver is the primary tissue expressing the anti-HER2 antibody.
Specificity of anti-HER2 antibody expressed in vivo
The expression cassettes for anti-HER2 and anti-HER2myc were packaged into the AAVrh.10 capsid and administered intravenously into C57Bl/6 mice. The specificity of anti-HER2 antibody expressed by AAVrh.10 in vivo to human HER2 was assessed by flow cytometry. The serum from AAVrh.10aHER2-myctreated mice specifically recognized HER2 þ BT474 cells but not HER2 À A673 cells (Figures 5a and b ). As controls, sera from PBS and AAVrh.10aPA-myc-treated mice did not recognize either of these cells (Figures 5c and d) . 
10aHER2-mediated anti-HER2 antibody expression
To evaluate the persistence of in vivo expression of anti-HER2 antibodies in the serum of C57Bl/6 mice, electrophoresis under non-reducing conditions followed by western blot analysis was used to detect the myc tag attached to the heavy chain. Pooled serum samples from AAVrh.10aHER2-treated mice taken at various time points were assessed. The western blot analysis showed that the myc-tagged anti-HER2 antibody was detectable at 1 week, peaked at about 5-24 weeks and was sustained for more than 1 year (Figure 6a ). The time course of expression of anti-HER2 antibodies in the serum following intravenous adminstration of AAVrh.10aHER2-myc in C57Bl/6 mice was quantitated using a human HER2-specific ELISA. The antibody was detectable by week 1, peaked at week 12 and slowly declined over 1 year (Figure 6b ). At 56 weeks, the last time point tested, the anti-HER2 antibody levels were still 12.2 ± 1.5 mg ml À1 . No anti-HER2 antibody was detected in the sera from control mice receiving AAVrh.10LacZ or from naive mice.
AAVrh.10aHER2-induced humoral anti-AAV and anti-idiotypic responses
For analysis of the humoral anti-adeno-associated virus (AAV) response, serum samples taken at various time points were assessed by ELISA against AAV capsid proteins. Anti-AAVrh.10 antibodies could be detected as early as 1 week after AAV administration, peaked at 2-3 weeks, and then slowly declined over 1 year (Figure 7a ). There were no detectable antibody responses against the capsid of a different AAV serotype (AAV6.2LacZ; Figure 7b ), showing the specificity of the anti-AAV humoral immune response. Figure 3 Inhibition of HER2 þ cell proliferation by anti-HER2 antibody expressed by pAAVaHER2 and pAAVaHER2-myc plasmids. Media were collected from 293 cells transfected with mock, pGFP, pAAVaPA-myc, pAAVaHER2, pAAVaHER2-myc and added to HER2 þ BT474 cells and HER2 À HeLa cells. After various time periods, cell proliferation was assessed. The data are expressed as the relative cell number compared with mock-medium-treated cells. Each point represents the mean of eight replicates. (a) Specific suppression of HER2 þ cell proliferation by anti-HER2 antibody expressed by the 293 cells. The medium from pGFP-, pAAVaHER2-, pAAVaHER2-myc-or pAAVaPA-myc-transfected cells was added to BT474 (HER2 þ ) or HeLa cells (HER2 À ) and cell proliferation was assessed after 3 days. (b) Dose-dependent suppression of HER2 þ cell proliferation by anti-HER2 antibody expressed by the 293 cells. The medium from pAAVaPA-myc-, pAAVaHER2-or pAAVaHER2myc-transfected cells was twofold serially diluted and then added to BT474 cells. After 5 days, cells proliferation was assessed. The possibility of an anti-idiotype response against genetically delivered anti-HER2 antibody was investigated by direct ELISA, in which microtiter plates were coated with purified anti-HER2-myc Fab fragments. The purity of the anti-HER2-myc Fab fragment was first verified by ELISA showing that the purified anti-HER2 Fab could be recognized by anti-mouse heavy and light chain antibody but not by anti-myc antibody or antimouse Fc antibody (that is, there was no residual Fc domain in the coating antigen). The integrity and the anti-HER2 functionality of the Fab fragment were further demonstrated by ELISA showing binding to the HER2 extracellular domain. Using ELISA with this verified anti-HER2 Fab, no anti-idiotypic antibodies were detectable in the serum from all AAVrh.10aHER2-myc treated mice assessed over 1 year (Figure 8 ).
Effects of AAVrh.10aHER2 on HER2 þ human tumor growth
To determine the effects of AAVrh.10-expressed anti-HER2 antibody on tumor growth in vivo, Balb/c nu/nu mice were treated with AAVrh.10aHER2-myc or with AAVrh.10aPA-myc and PBS as controls. After 21 days, tumors were generated by implanting HER2-overexpressing Calu-3 cells subcutaneously onto the right flank of the mice. Tumor growth was determined by measuring the tumor volume every 3-4 days post-vector administration. Intravenous administration of AAVrh.10aHER2-myc to nude mice induced a significant suppression of Calu-3 tumor growth relative to animals that received AAVrh.10aPA-myc or PBS (Po0.01 compared with all other groups, Figure 9a ). The survival of Calu-3 tumor-bearing mice was also monitored (Figure 9b) . In contrast to mice that received AAVrh.10aPA-myc or PBS, mice treated with AAVrh.10aHER2-myc exhibited a significant survival advantage (Po0.01 compared with all other groups).
Discussion
There are now over 20 US Food and Drug Administration-approved therapeutic monoclonal antibodies for the treatment of cancer and of autoimmune, inflammatory and infectious diseases, with many more in preclinical and clinical development. 22 Chronic diseases such as cancer require long-term and repeated administration of the therapeutic mAb over time. Trastuzumab, a humanized --PBS -AAVαHER2-myc 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 Figure 5 HER2-specific cell binding from aHER2 antibody expressed in vivo following the administration of AAVrh.10aHER2. PBS, AAVrh.10aHER2-myc or AAVrh.10aPA-myc (10 11 genome copies each) was administered intravenously into C57Bl/6 mice and after 30 days the serum was collected and pooled and used as the primary antibody. HER2 þ BT474 cells (a, b) and HER2 À A673 cells (c, d) were exposed to sera using fluorescein isothiocyanate-labeled goat anti-mouse antibody and flow cytometry for detection. Solid lines: AAVrh.10aPA-myc sera or AAVrh.10aHER2-myc sera. Dashed lines: PBS control sera. (a) BT474 cells were exposed to sera from mice receiving the control vector AAVrh.10aPA-myc or PBS. (b) BT474 cells were exposed to sera from mice receiving AAVrh.10aHER2-myc or PBS. (c) A673 cells were exposed to sera from mice receiving the control vector AAVrh.10aPA-myc or PBS. (d) A673 cells were exposed to sera from mice receiving AAVrh.10aHER2-myc or PBS.
AAVrh.10-mediated expression of herceptin G Wang et al monoclonal anti-HER2 antibody, is effective in the treatment of HER2-overexpressing breast cancer. 8 In this study, we show that a single administration of an AAVrh.10 vector encoding the murine equivalent of Trastuzumab specific for human HER2 expressed anti-HER2 primarily in the liver and persisted for at least 1 year without inducing an anti-idiotype response, and resulted in slower growth of xenografted human tumors in mice.
Trastuzumab (Herceptin)
Trastuzumab was derived from the murine anti-HER2 mAb 4D5. 2, 10 Humanization of 4D5 to reduce immunogenicity and to increase the half-life in humans resulted in an antibody molecule that is 95% human and 5% murine but retaining the same biochemical and pharmacological properties of the parental antibody. 10, 23 In preclinical studies with immunodeficient mice, trastuzumab effectively inhibited the growth of various implanted human tumors overexpressing HER2. 24, 25 The mechanism of action of trastuzumab includes initiation of G1 arrest and induction of p27, inhibition of HER2 shedding, inhibition of the phosphoinositide 3-K pathway, inhibition of angiogenesis and induction of immune mechanism. 26 The initial clinical trials of trastuzumab tested it as a single agent in HER2-overexpressing metastatic breast cancer, with resulting response rates of 12-34% for a median duration of 9 months. Phase III trials combining trastuzumab with paclitaxel or docetaxel showed increased response rates, time to disease progression and overall survival compared with trastuzumab monotherapy. 8 The recommended duration of trastuzumab treatment is currently 1 year (adjuvant) or until the progression of the disease (for example, metastatic disease). In spite of the encouraging clinical results, the high cost of trastuzumab has evoked a heated debate.
Genetic antibody-based immunotherapy Because of the costs and time involved in producing and manufacturing monoclonal antibodies, genetic transfer of therapeutic antibodies became an attractive strategy as both short-term and long-term therapy. 27, 28 Initially gene therapy was used to deliver single-chain antibodies, but this strategy has some inherent limitations. Compared with full-length antibodies, single-chain antibodies have a short half-life, fast clearance, low affinity, lack of Fc functional domain and inability to induce antibody-dependent cellular cytotoxicity and complement AAVrh.10-mediated expression of herceptin G Wang et al dependent cytotoxicity, all contributing to reduce their efficacy. 29 The challenge for successful genetic delivery of full-length antibodies is to find ways of generating stoichiometric amounts of both the heavy and light chains in the antibody-producing cells. 28 Various expression methods have been developed utilizing mono-and bi-cistronic expression cassettes encoded on one or two vectors. 30 The use of a single vector with two identical promoters or two different promoters for stable expression introduces the risk of recombination events or may result in unbalanced expression of the two different chains. 30 In contrast, internal ribosome entry sites allow the coexpression of multiple polypeptide chains from the same mRNA and have been used to express full-length antibodies successfully both in vitro and in vivo. [31] [32] [33] However, this method is both cell and gene dependent and can often result in lower expression of the gene encoded by the second cistron. 34 An antibody expression system that uses the foot-and-mouth-disease virus-derived 2A self-processing sequence to express full-length antibodies from a single open reading frame was first described by Fang et al. 12 In the current study, the foot-and-mouthdisease virus-2A-based cassette was used, yielding an apparent equimolar antibody expression of heavy chain and light chain, with functional full-length anti-HER2 Anti-tumor efficacy mediated by AAVrh.10aHER2. On day 0, Balb/c nu/nu mice received intravenous administration of 10 11 genome copies of AAVrh.10aHER2-myc (n ¼ 7) or of AAVrh.10aPAmyc (n ¼ 5) or PBS (n ¼ 5) as controls. After 21 days, Calu-3 tumor cells (10 7 ) were implanted subcutaneously in the right flank of the mice. (a) Tumor volume was assessed 2 times weekly and is given as the average tumor volume (mm 3 ) ± s.e. (b) Survival of AAVrh. 10aHER2-myc-treated Calu-3 tumor-bearing mice. Survival is presented as the % of surviving mice in each group.
AAVrh.10-mediated expression of herceptin G Wang et al antibody generated in both immune-competent and immune-compromised mice.
Although antibodies have been expressed in vivo using plasmids or cells transduced with retroviral vectors, these approaches achieved only marginal levels of antibody production. 35, 36 In contrast, high therapeutic antibody level has been achieved with adenovirus and adenoassociated virus (AAV) vectors. With adenovirus as a platform, detectable serum CD20 antibody level was obtained in nude mice from day 3 through at least 8 weeks post-administration, levels high enough for complete elimination of pre-established B-cell lymphoma cells in nude mice. 37 A single administration of an adenovirus encoding anti-VEGF antibody suppresses the proliferation and vascularity of pre-existing human tumors in immunodeficient mice, with concomitant suppression of the growth of tumors and increased survival of the tumorbearing mice. 33 With adeno-associated virus (AAV) as a platform, high-level and long-term antibody expression has been achieved by using various serotypes, including AAV8, 12 AAVrh.10 13 and AAV1. 38 Relevant to expressing HER2 antibodies, delivery of a gene encoding an anti-HER2 intracellular single-chain antibody resulted in downregulation of cell surface HER2 levels and induction of apoptosis in HER2-overexpressing cancer cells. 39, 40 A single-chain anti-HER2 antibody linked to caspase 6, a pro-apoptotic molecule, generated a chimeric HER2-targeted toxic protein. 41 More recently, an adenovirus was used to express full-length HER2 antibody, resulting in high transient anti-HER2 antibody levels with concomitant tumor suppression in nude mice. 42 In the present study, a single AAVrh.10-mediated genetic delivery of an anti-HER2 antibody suppressed but did not reverse the growth of HER2 þ tumors, possibly due to the sensitivity of Calu-3 cells to HER2 antibody. Expression of anti-HER2 might be enhanced if the vector was further optimized. Instead of cytomegalovirus promoter, cytomegalovirus enhancer/chicken b-actin/ rabbit b-globin hybrid promoter, elongation factor-1a, phosphoglycerokinase or other promoters might be used to provide enhanced antibody gene expression in vivo. 43 To enhance gene expression posttranscriptionally, the woodchuck hepatitis virus posttranscriptional regulatory element can also be used. 44 Codon and GC content optimization of expression cassette might also help.
Immune responses
One therapeutical concern using genetic delivery of antibodies is that the viral vector will induce corresponding anti-virus antibodies. 45 In the current study, we found that AAVrh.10 coding for anti-HER2 induces an anti-AAVrh.10 response in immune-competent mice, but longterm expression will still be observed for at least 1 year. Compared with liver and other major target organs of AAVrh.10, the immune organs spleen and thymus only have negligible transgene expression after intravenous administration of AAVrh.10.
Another therapeutical concern is in the development of anti-idiotype antibodies, in that high dose and repeated administration of monoclonal antibodies can result in anti-idiotype responses. 46 In addition, the ability of virus vectors to stimulate an immune response against ectopic proteins expressed from the transgene they carry makes the immune responses to genetically delivered antibodies more likely. 47 With adenovirus as a platform, high levels of circulating ectopic monoclonal antibodies were obtained following in vivo gene transfer without inducing an anti-idiotype response sufficiently robust to exert a neutralizing effect. 32 Consistent with this observation, following AAVrh.10aaHER2 administration in immunecompetent mice in the present study, no anti-idiotype antibodies were observed.
